Ramon Mangues

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8455487/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation. Cancer Cell, 2012, 22, 571-584.	16.8	881
2	The Intestinal Stem Cell Signature Identifies Colorectal Cancer Stem Cells and Predicts Disease Relapse. Cell Stem Cell, 2011, 8, 511-524.	11.1	811
3	Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial Cell Factories, 2016, 15, 33.	4.0	265
4	Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7258-7263.	7.1	241
5	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. Cancer Research, 2013, 73, 1287-1297.	0.9	144
6	Orthotopic Microinjection of Human Colon Cancer Cells in Nude Mice Induces Tumor Foci in All Clinically Relevant Metastatic Sites. American Journal of Pathology, 2007, 170, 1077-1085.	3.8	140
7	uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. Oncotarget, 2016, 7, 57351-57366.	1.8	120
8	Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling andÂPTHLH. Nature Cell Biology, 2014, 16, 685-694.	10.3	117
9	Mouse models in oncogenesis and cancer therapy. Clinical and Translational Oncology, 2006, 8, 318-329.	2.4	116
10	K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts. Cancer Research, 2005, 65, 5512-5515.	0.9	110
11	Protein-Based Therapeutic Killing for Cancer Therapies. Trends in Biotechnology, 2018, 36, 318-335.	9.3	98
12	<i>In Vivo</i> Architectonic Stability of Fully <i>de Novo</i> Designed Protein-Only Nanoparticles. ACS Nano, 2014, 8, 4166-4176.	14.6	89
13	Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene, 1997, 14, 1361-1370.	5.9	72
14	<scp>CXCR4</scp> expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. Journal of Pathology, 2015, 235, 445-455.	4.5	71
15	Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials, 2012, 33, 8714-8722.	11.4	65
16	Towards protein-based viral mimetics for cancer therapies. Trends in Biotechnology, 2015, 33, 253-258.	9.3	65
17	Isolation of High Molecular Weight DNA for Reliable Genotyping of Transgenic Mice. BioTechniques, 1997, 22, 1114-1119.	1.8	64
18	Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	64

#	Article	IF	CITATIONS
19	Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget, 2015, 6, 29016-29033.	1.8	62
20	Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. International Journal of Nanomedicine, 2012, 7, 4533.	6.7	61
21	Bottomâ€Up Instructive Quality Control in the Biofabrication of Smart Protein Materials. Advanced Materials, 2015, 27, 7816-7822.	21.0	61
22	K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis, 2006, 27, 2190-2200.	2.8	58
23	Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. Journal of Controlled Release, 2018, 274, 81-92.	9.9	55
24	Gated Mesoporous Silica Nanoparticles Using a Doubleâ€Role Circular Peptide for the Controlled and Targetâ€Preferential Release of Doxorubicin in CXCR4â€Expresing Lymphoma Cells. Advanced Functional Materials, 2015, 25, 687-695.	14.9	54
25	A Critical Role for Rac1 in Tumor Progression of Human Colorectal Adenocarcinoma Cells. American Journal of Pathology, 2008, 172, 156-166.	3.8	52
26	Assembly of histidine-rich protein materials controlled through divalent cations. Acta Biomaterialia, 2019, 83, 257-264.	8.3	49
27	Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells. Journal of Controlled Release, 2020, 320, 96-104.	9.9	48
28	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB Journal, 2015, 29, 464-476.	0.5	43
29	Divalent Cations: A Molecular Glue for Protein Materials. Trends in Biochemical Sciences, 2020, 45, 992-1003.	7.5	42
30	Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. European Journal of Haematology, 2013, 91, 209-218.	2.2	41
31	Selective CXCR4 ⁺ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin. Small, 2018, 14, e1800665.	10.0	40
32	Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci. Advanced Materials, 2020, 32, e1907348.	21.0	40
33	An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. Journal of Hematology and Oncology, 2020, 13, 36.	17.0	39
34	<i>Ku</i> 70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. International Journal of Cancer, 2008, 123, 1068-1079.	5.1	38
35	Modular Protein Engineering in Emerging Cancer Therapies. Current Pharmaceutical Design, 2009, 15, 893-916.	1.9	38
36	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. Haematologica, 2020, 105, 741-753.	3.5	36

#	Article	IF	CITATIONS
37	Artificial Inclusion Bodies for Clinical Development. Advanced Science, 2020, 7, 1902420.	11.2	36
38	Site-Dependent E-Cadherin Cleavage and Nuclear Translocation in a Metastatic Colorectal Cancer Model. American Journal of Pathology, 2010, 177, 2067-2079.	3.8	35
39	Codon 12 and codon 13 mutations at the Kâ€ras gene induce different soft tissue sarcoma types in nude mice. FASEB Journal, 2002, 16, 1642-1644.	0.5	34
40	Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. International Journal of Cancer, 2006, 118, 2381-2389.	5.1	34
41	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 + colorectal cancer models. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1987-1996.	3.3	34
42	Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells. Scientific Reports, 2017, 7, 13946.	3.3	34
43	Peptideâ€Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4 ⁺ Solid Tumors. Advanced Functional Materials, 2017, 27, 1700919.	14.9	32
44	Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma. Carcinogenesis, 2012, 33, 1707-1716.	2.8	31
45	Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach. Journal of Controlled Release, 2018, 279, 29-39.	9.9	30
46	Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome. Blood, 2021, 137, 994-999.	1.4	30
47	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports, 2016, 6, 35765.	3.3	28
48	Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma. Head and Neck, 2019, 41, 429-439.	2.0	28
49	Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 535-541.	3.3	27
50	NF1 inactivation cooperates with N-Ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene, 1998, 17, 1705-1716.	5.9	26
51	Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1241-1251.	3.3	26
52	Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity. Acta Biomaterialia, 2017, 60, 256-263.	8.3	26
53	S49 Cells Endogenously Express Subtype 2 Somatostatin Receptors Which Couple to Increase Protein Tyrosine Phosphatase Activity in Membranes and Down-regulate Raf-1 Activity In Situ. Cellular Signalling, 1997, 9, 539-549.	3.6	25
54	Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles. Pharmaceutics, 2020, 12, 1004.	4.5	25

#	Article	IF	CITATIONS
55	Engineering tumor cell targeting in nanoscale amyloidal materials. Nanotechnology, 2017, 28, 015102.	2.6	24
56	CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 49.	8.6	24
57	Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis, 2003, 25, 535-539.	2.8	22
58	Selective delivery of T22-PE24-H6 to CXCR4 ⁺ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. Theranostics, 2020, 10, 5169-5180.	10.0	22
59	Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Oncotarget, 2017, 8, 38193-38213.	1.8	22
60	Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its <i>in vivo</i> synergism with gemcitabine. DMM Disease Models and Mechanisms, 2016, 9, 1461-1471.	2.4	21
61	Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Nanoscale, 2017, 9, 6427-6435.	5.6	21
62	Protein-driven nanomedicines in oncotherapy. Current Opinion in Pharmacology, 2019, 47, 1-7.	3.5	21
63	A celecoxib derivative inhibits focal adhesion signaling and induces caspaseâ€8â€dependent apoptosis in human acute myeloid leukemia cells. International Journal of Cancer, 2008, 123, 217-226.	5.1	20
64	Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine, 2016, 11, 1333-1336.	3.3	20
65	Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. FASEB Journal, 2002, 16, 975-982.	0.5	19
66	A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. Blood, 2011, 118, 4411-4420.	1.4	18
67	Carbon metabolism and the sign of control coefficients in metabolic adaptations underlying K-ras transformation. Biochimica Et Biophysica Acta - Bioenergetics, 2011, 1807, 746-754.	1.0	18
68	Conformational Conversion during Controlled Oligomerization into Nonamylogenic Protein Nanoparticles. Biomacromolecules, 2018, 19, 3788-3797.	5.4	18
69	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	3.5	17
70	Bobel-24 and Derivatives Induce Caspase-Independent Death in Pancreatic Cancer Regardless of Apoptotic Resistance. Cancer Research, 2008, 68, 6313-6323.	0.9	16
71	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advancedâ€stage head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E1392-403.	2.0	16
72	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. International Journal of Nanomedicine, 2021, Volume 16, 1869-1888.	6.7	16

#	Article	IF	CITATIONS
73	GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Delivery, 2022, 29, 1384-1397.	5.7	16
74	Endosomal escape of protein nanoparticles engineered through humanized histidine-rich peptides. Science China Materials, 2020, 63, 644-653.	6.3	15
75	Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. Acta Pharmaceutica Sinica B, 2022, 12, 2578-2591.	12.0	15
76	A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity. Acta Biomaterialia, 2020, 113, 584-596.	8.3	14
77	Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles. Acta Biomaterialia, 2021, 119, 312-322.	8.3	14
78	Absence ofMDM-2 gene amplification in experimentally induced tumors regardless ofp53 status. Molecular Carcinogenesis, 1994, 9, 40-45.	2.7	13
79	High RAB 25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma. Cancer Medicine, 2013, 2, 950-963.	2.8	13
80	Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. Microbial Cell Factories, 2016, 15, 59.	4.0	13
81	Self-assembling as regular nanoparticles dramatically minimizes photobleaching of tumour-targeted GFP. Acta Biomaterialia, 2020, 103, 272-280.	8.3	13
82	In Vitro Fabrication of Microscale Secretory Granules. Advanced Functional Materials, 2021, 31, 2100914.	14.9	13
83	Engineering multifunctional protein nanoparticles by <i>in vitro</i> disassembling and reassembling of heterologous building blocks. Nanotechnology, 2017, 28, 505102.	2.6	12
84	Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1777-1786.	3.3	12
85	A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. Biomaterials, 2022, 280, 121258.	11.4	12
86	Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc. Molecular Cancer Therapeutics, 2006, 5, 1166-1175.	4.1	11
87	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer. Acta Biomaterialia, 2019, 99, 426-432.	8.3	11
88	Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles. Nanotechnology, 2019, 30, 115101.	2.6	11
89	Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering. Science China Materials, 2020, 63, 147-156.	6.3	11
90	Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers. Cancers, 2021, 13, 2929.	3.7	11

#	Article	IF	CITATIONS
91	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. Journal of Controlled Release, 2021, 335, 117-129.	9.9	11
92	CXCR4 ⁺ -targeted protein nanoparticles produced in the food-grade bacterium <i>Lactococcus lactis</i> . Nanomedicine, 2016, 11, 2387-2398.	3.3	10
93	CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis. PLoS ONE, 2018, 13, e0198789.	2.5	10
94	Ion-dependent slow protein release from <i>inÂvivo</i> disintegrating micro-granules. Drug Delivery, 2021, 28, 2383-2391.	5.7	10
95	Focal adhesion protein expression in human diffuse large Bâ€cell lymphoma. Histopathology, 2014, 65, 119-131.	2.9	9
96	Nanostructure Empowers Active Tumor Targeting in Ligandâ€Based Molecular Delivery. Particle and Particle Systems Characterization, 2019, 36, 1900304.	2.3	9
97	The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelialâ€like head and neck carcinoma subtypes. Head and Neck, 2019, 41, 1830-1845.	2.0	9
98	Engineering Protein Venoms as Selfâ€Assembling CXCR4â€Targeted Cytotoxic Nanoparticles. Particle and Particle Systems Characterization, 2020, 37, 2000040.	2.3	9
99	Promoter demethylation in MMTV/N-rasN transgenic mice required for transgene expression and tumorigenesis. Molecular Carcinogenesis, 1995, 14, 94-102.	2.7	8
100	Subcutaneous preconditioning increases invasion and metastatic dissemination in colorectal cancer models. DMM Disease Models and Mechanisms, 2014, 7, 387-96.	2.4	8
101	Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability. Materials Letters, 2015, 154, 140-143.	2.6	8
102	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. Cancers, 2018, 10, 436.	3.7	8
103	Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines. Acta Biomaterialia, 2021, 130, 211-222.	8.3	8
104	Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics, 2022, 14, 192.	4.5	8
105	Targeting in Cancer Therapies. Medical Sciences (Basel, Switzerland), 2016, 4, 6.	2.9	7
106	Efficient bioactive oligonucleotideâ€protein conjugation for cellâ€ŧargeted cancer therapy. ChemistryOpen, 2019, 8, 382-387.	1.9	7
107	Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. Journal of Controlled Release, 2022, 343, 277-287.	9.9	7
108	Developing Protein–Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial Agents. ACS Applied Materials & Interfaces, 2020, 12, 57746-57756.	8.0	6

#	Article	IF	CITATIONS
109	Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease. Biomedicines, 2022, 10, 1680.	3.2	6
110	Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma. Clinical and Experimental Metastasis, 2012, 29, 339-347.	3.3	5
111	<i>NEDD9</i> , an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. Oncotarget, 2017, 8, 76003-76014.	1.8	5
112	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics, 2021, 13, 1922.	4.5	5
113	A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model. Pharmaceutics, 2022, 14, 887.	4.5	5
114	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. Biomedicine and Pharmacotherapy, 2022, 150, 112940.	5.6	4
115	A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement. Haematologica, 2013, 98, 1242-1249.	3.5	3
116	Targeting low-density lipoprotein receptors with protein-only nanoparticles. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	2
117	Improved performance of proteinâ€based recombinant gene therapy vehicles by tuning downstream procedures. Biotechnology Progress, 2013, 29, 1458-1463.	2.6	1
118	Immunostaining Protocol: P-Stat3 (Xenograft and Mice). Bio-protocol, 2014, 4, .	0.4	0